PURPOSE: Ixabepilone is one of the epothilones, a new class of cytotoxics, that function as microtubule-stabilizing agents. With the primary endpoint of assessing ixabepilone's response rate against metastatic gastric cancer previously treated with a taxane, we performed a multi-center phase II trial. PATIENTS AND METHODS: Patients with histologically documented metastatic gastric or gastroesophageal adenocarcinoma, who had previously received a taxane, were eligible. Patients were required to have near normal organ function, > or =18 years of age, ECOG performance status of 0 or 1. A written informed consent was obtained from all patients. Ixabepilone was administered over one hour intravenously at a dose of 50 mg/m2 every 21 days (23 patients; cohort A) and 24 subsequent patients were treated with an amended protocol schedule to receive 6 mg/m2 intravenously on days 1-5 every 21 days (cohort B). RESULTS: A total of 47 patients were treated. Most patients were men with a median performance status of 1. Two of 23 patients in cohort A achieved a confirmed partial response (9%, 95% CI 1.1-28%) but none of the 24 patients in cohort B achieved a response. A higher proportion of patients in cohort A experienced Grade 3/4 toxicities compared with those in cohort B. CONCLUSIONS: Ixabepilone, on a once every 21-day schedule, is modestly active against metastatic gastric cancer previously treated with a taxane. The days 1-5 every 21 days schedule had a more favorable safety profile but no activity. The results of this study suggest that once every 21-day ixabepilone schedule should be pursued further in untreated gastric or gastroesophageal adenocarcinoma patients.
PURPOSE:Ixabepilone is one of the epothilones, a new class of cytotoxics, that function as microtubule-stabilizing agents. With the primary endpoint of assessing ixabepilone's response rate against metastatic gastric cancer previously treated with a taxane, we performed a multi-center phase II trial. PATIENTS AND METHODS: Patients with histologically documented metastatic gastric or gastroesophageal adenocarcinoma, who had previously received a taxane, were eligible. Patients were required to have near normal organ function, > or =18 years of age, ECOG performance status of 0 or 1. A written informed consent was obtained from all patients. Ixabepilone was administered over one hour intravenously at a dose of 50 mg/m2 every 21 days (23 patients; cohort A) and 24 subsequent patients were treated with an amended protocol schedule to receive 6 mg/m2 intravenously on days 1-5 every 21 days (cohort B). RESULTS: A total of 47 patients were treated. Most patients were men with a median performance status of 1. Two of 23 patients in cohort A achieved a confirmed partial response (9%, 95% CI 1.1-28%) but none of the 24 patients in cohort B achieved a response. A higher proportion of patients in cohort A experienced Grade 3/4 toxicities compared with those in cohort B. CONCLUSIONS:Ixabepilone, on a once every 21-day schedule, is modestly active against metastatic gastric cancer previously treated with a taxane. The days 1-5 every 21 days schedule had a more favorable safety profile but no activity. The results of this study suggest that once every 21-day ixabepilone schedule should be pursued further in untreated gastric or gastroesophageal adenocarcinomapatients.
Authors: F Y Lee; R Borzilleri; C R Fairchild; S H Kim; B H Long; C Reventos-Suarez; G D Vite; W C Rose; R A Kramer Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: R A Newman; J Yang; M Raymond; V Finlay; F Cabral; D Vourloumis; L C Stephens; P Troncoso; X Wu; C J Logothetis; K C Nicolaou; N M Navone Journal: Cancer Chemother Pharmacol Date: 2001-10 Impact factor: 3.333
Authors: Jennifer A Low; Suparna B Wedam; James J Lee; Arlene W Berman; Adam Brufsky; Sherry X Yang; Marianne S Poruchynsky; Seth M Steinberg; Nitin Mannan; Tito Fojo; Sandra M Swain Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Matthew D Galsky; Eric J Small; William K Oh; Isan Chen; David C Smith; A Dimitrios Colevas; Lou Martone; Tracy Curley; Anthony Delacruz; Howard I Scher; W Kevin Kelly Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: D M Bollag; P A McQueney; J Zhu; O Hensens; L Koupal; J Liesch; M Goetz; E Lazarides; C M Woods Journal: Cancer Res Date: 1995-06-01 Impact factor: 12.701
Authors: L Sepp-Lorenzino; A Balog; D-S Su; D Meng; N Timaul; H I Scher; S J Danishefsky; N Rosen Journal: Prostate Cancer Prostatic Dis Date: 1999-01 Impact factor: 5.554
Authors: Jason Konner; Rachel N Grisham; Jae Park; Owen A O'Connor; Gillian Cropp; Robert Johnson; Alison L Hannah; Martee L Hensley; Paul Sabbatini; Svetlana Mironov; Svetlana Miranov; Samuel Danishefsky; David Hyman; David R Spriggs; Jakob Dupont; Carol Aghajanian Journal: Invest New Drugs Date: 2011-11-10 Impact factor: 3.850
Authors: Brigitte C Widemann; Wendy Goodspeed; Anne Goodwin; Tito Fojo; Frank M Balis; Elizabeth Fox Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: Pamela L Kunz; Aiwu R He; A Dimitrios Colevas; Michael J Pishvaian; Jimmy J Hwang; Pamela L Clemens; Marianne Messina; Remigiusz Kaleta; Fernanda Abrahao; Branimir I Sikic; John L Marshall Journal: Invest New Drugs Date: 2012-02-14 Impact factor: 3.850
Authors: Patrick A Ott; Anne Hamilton; Amanda Jones; Naomi Haas; Tsiporah Shore; Sandra Liddell; Paul J Christos; L Austin Doyle; Michael Millward; Franco M Muggia; Anna C Pavlick Journal: PLoS One Date: 2010-01-20 Impact factor: 3.240